Blog
RSS FeedPosted by Michael Wonder on 04 Mar 2020
Expanding access and reducing prices for drugs to prevent HIV. Should Government enforce its patent rights against the pharmaceutical industry?
3 March 2020 - On November 6, 2019, the Department of Health and Human Services (HHS) filed a lawsuit against Gilead ...
Posted by Michael Wonder on 04 Mar 2020
Drug shortages in the United States. Are some prices too low?
3 March 2020 - The US public identified lowering prescription drug prices as the top health priority for Congress in 2019. ...
Posted by Michael Wonder on 04 Mar 2020
Anti-flu pill can fight illness as soon as symptoms show
4 February 2020 - A new pill that can fight the flu as soon as symptoms strike has been approved ...
Posted by Michael Wonder on 04 Mar 2020
Estimated research and development investment needed to bring a new medicine to market, 2009-2018
3 March 2020 - In this study, which included 63 of 355 new therapeutic drugs and biologic agents approved by the ...
Posted by Michael Wonder on 04 Mar 2020
Alnylam announces approval of Givlaari (givosiran) in the European Union for the treatment of acute hepatic porphyria in adults and adolescents
3 March 2020 - Givlaari approved based on ENVISION Phase 3 study results showing a 74% reduction in the rate of ...
Posted by Michael Wonder on 04 Mar 2020
Novartis receives Health Canada approval for Mayzent (siponimod) to treat secondary progressive multiple sclerosis with active disease
3 March 2020 - Approval is based on the Phase III EXPAND trial, the largest controlled clinical study of people living ...
Posted by Michael Wonder on 03 Mar 2020
Ayala Pharmaceuticals granted U.S. FDA fast track designation for AL101 for the treatment of recurrent or metastatic adenoid cystic carcinoma
3 March 2020 - Ayala Pharmaceuticals today announced that the U.S. FDA has granted fast track designation to AL101 for ...
Posted by Michael Wonder on 03 Mar 2020
FDA grants rare paediatric disease designation to Stealth BioTherapeutics for elamipretide for the treatment of Barth syndrome
3 March 2020 - Stealth BioTherapeutics today announced that the U.S. FDA has granted rare paediatric disease designation for elamipretide ...
Posted by Michael Wonder on 03 Mar 2020
The coronavirus could help pharma reset its reputation in Washington
3 March 2020 - The coronavirus outbreak could be the pharmaceutical industry’s ticket to saving its reputation in Washington. ...
Posted by Michael Wonder on 03 Mar 2020
FDA grants breakthrough therapy designation for Genentech’s Esbriet (pirfenidone) in unclassifiable interstitial lung disease
2 March 2020 - There are currently no FDA approved treatments for unclassifiable ILD, a debilitating, severe respiratory condition. ...
Posted by Michael Wonder on 03 Mar 2020
Sebela Pharmaceuticals announces FDA approval of Pizensy for oral solution for the treatment of chronic idiopathic constipation in adults
2 March 2020 - Sebela seeks partner to commercialise in the U.S. ...
Posted by Michael Wonder on 03 Mar 2020
'Get it done. We need it': Trump's coronavirus message to big pharma
3 March 2020 - President Donald Trump sought to show his personal engagement in the fight against coronavirus, meeting with ...
Posted by Michael Wonder on 03 Mar 2020
Mallinckrodt initiates rolling submission of new drug application to the U.S. FDA for terlipressin for the treatment of patients with hepatorenal syndrome type 1
2 March 2020 - Terlipressin would be the first FDA-approved treatment option in the United States for patients with HRS-1 if ...
Posted by Michael Wonder on 03 Mar 2020
Extended-release drugs could be costing U.S. health care system billions
1 March 2020 - If doctors prescribed short-acting medications that must be taken twice a day instead of once-a-day extended-release ...
Posted by Michael Wonder on 03 Mar 2020
Cablivi (caplacizumab) approved by Health Canada for adults living with acquired thrombotic thrombocytopenic purpura
2 March 2020 - Cablivi is the first treatment approved in Canada for aTTP, a life-threatening blood clotting disorder. ...